• The PlexABMR test measures the risk of rejection in which B-cells play a major role by producing antibodies against the transplanted organ.
• Antibody-mediated rejection (ABMR) is a less common form of rejection compared with cellular rejection, however, it has been linked to accelerated graft loss.
• Antibody-mediated rejection can accompany cellular rejection and requires different drugs than cellular rejection. It is not easily distinguished from acute cellular rejection.
• ABMR often accompanies acute cellular rejection and other types of injury on a biopsy.
• Information about the risk of ABMR can facilitate early preventive measures, drug selection, treatment, and improve graft health as well as longevity.
• This test is under development. If you are interested in learning more, please subscribe to our updates.
• For details on the clinical trials conducted, please check this link.

The PlexABMR test measures the risk of Antibody-mediated rejection in which B-cells play a major role by producing antibodies against the transplanted organ.